19:59:12 EST Tue 10 Dec 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Cognetivity Neurosciences Ltd
Symbol CGN
Shares Issued 41,447,022
Close 2019-03-13 C$ 0.39
Recent Sedar Documents

Cognetivity subsidiary receives certification for QMS

2019-03-13 09:39 ET - News Release

Dr. Sina Habibi reports

COGNETIVITY NEUROSCIENCES SECURES CRITICAL QUALITY STANDARD CERTIFICATION

Cognetivity Neurosciences Ltd.'s wholly owned subsidiary, Cognetivity Ltd., has received ISO 13485:2016 certification for its quality management system (QMS) following review by Lloyd's Register Quality Assurance Ltd. ISO 13485:2016 is an internationally recognized quality standard specific to the medical device industry, and its award demonstrates Cognetivity's commitment to the highest level of medical device quality controls and to meeting customer and international regulatory expectations. The certification is a critical prerequisite to securing regulatory approval around the world, including European CE marking and other regulatory certifications.

ISO 13485:2016 is the international standard for quality management systems for medical devices, under which an organization has shown via an in-depth auditing process that it is able to create medical devices and related services that meet applicable regulatory requirements. ISO is an independent, non-governmental, global organization that sets standards for compliance with industry-best practices, and in May, 2018, the United States Food and Drug Administration (FDA) announced its intention to use ISO 13485:2016 as the new basis for its future quality system legislation.

"This ISO 13485 certification represents a key milestone on the path towards the full commercialization of our ICA tool. It illustrates our commitment to quality, our ability to reach the stringent criteria required for certification and further reinforces our dedication to ensuring our ICA platform is able to help as many people as possible in this critical area for health care," said Cognetivity chief executive officer Dr. Sina Habibi.

With this certification, Cognetivity will be in a position to be able to proceed toward a CE Mark application in Europe, a Health Canada medical device licence application for Canada and a Therapeutic Goods Association application for Australia once its clinical validation study is completed.

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company developing a cognitive testing platform, the integrated cognitive assessment (ICA), for use in medical and commercial environments. Cognetivity's ICA uses artificial intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.

We seek Safe Harbor.

© 2019 Canjex Publishing Ltd. All rights reserved.